Paris, France and Camberley, UK – 21 December 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international expert in clinical epidemiology, is announcing, following a new variant of COVID-19 detection by COVID19 Genomics UK UK consortium, known as VUI-202012/01, the Company has analyzed the mutations in this new variant and in its all COVID-19 strains have been published to fully evaluate the reliability of existing diagnostic tests.
Image credit: Shutterstock / CKA
The results of the in-silico analysis (computer simulation) of the series mutations show that the Company’s polymerase chain reaction output package, based around a one- and two-gene target for COVID-19, is still capable of all published COVID-19 species detected with the same high level of accuracy, introducing VUI-202012/01.
The Company notes that this new strain of the virus has been identified in other countries, including the Netherlands, Denmark and Australia.
Graham Mullis, Novacyt Chief Executive, said: “This data supports the continued use of our tests, which remain accurate in detecting all published types of COVID-19, including the latest version. As part of our study program, we are committed to analyzing our selected gene targets for COVID-19 against newly published viral sequences to demonstrate continued accuracy and performance. We will also be in close contact with the Department of Health and Social Care and the NHS as we continue to focus our efforts on rolling out our tests to hospitals and laboratories across the UK, as well as our messengers all over the world. ”
Please contact
Novacyt SA
Graham Mullis, Chief Executive
Anthony Dyer, Chief Financial Officer
+44 (0) 1276 600081
SP Angel Corporate Finance LLP (Designated Advisor and Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0) 20 3470 0470
Numis Securities Limited (Joint Broker)
Freddie Barnfield / Seumas Black
+44 (0) 20 7260 1000
Allegra Finance (French List Assistant)
Rémi Durgetto / Yannick Petit
+33 (1) 42 22 10 10
[email protected] / [email protected]
FTI Consulting (International)
Victoria Foster Mitchell / Alex Shaw / Mary Whittow
+44 (0) 20 3727 1000
[email protected] / [email protected] / [email protected]
FTI Consulting (France)
Arnaud de Cheffontaines
+33 (0) 147 03 69 48
[email protected]
About Novacyt Group
Novacyt Group is an international diagnostic business that generates a growing package of in vitro and diagnostic tests. Its key strengths are in product development diagnostics, commercialization, contract design and manufacturing. The Company’s core business units are comprised of Primerdesign and Lab21 Products, providing a wide range of high-quality appraisals and feedback worldwide. The Group directly serves the microbiology, hematology and serology markets as do their global partners, which include major corporate organizations.
For more information check out the website: www.novacyt.com